The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

Obesity and diabetes are closely linked, but the good news is that both are preventable and manageable with early ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Obesity is common in our society for humans and our pets. Spring is a good time to consider the impacts of winter ...

A new study found more than two-thirds of Reserve and Guard troops are overweight, prompting a scathing rebuke of lax ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only ...

Yet the disparities by sex, race/ethnicity, and location pale in comparison to a striking overall lack of adoption.

Researchers found that the impact of polyphenols rutin and genistein on the human fecal metabolome varies significantly by ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...